Skip to main content

Advertisement

Table 1 Characteristics of publications included in the meta-analysis

From: Gadolinium-enhanced cardiac magnetic resonance imaging: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines

Year Studies Participants Age (years) Perfusion studies LGE studies Median GBCA dose (mmol/Kg)* Mean GBCA dose (mmol/Kg)*
2004 22 (9.5) 697 (3.5) 56.1±8.7 6 (17.6) 16 (8.1) 0.15 0.16±0.06
2005 19 (8.2) 2,123 (10.7) 54.4±8.4 2 (5.9) 17 (8.6) 0.2 0.19±0.03
2006 26 (11.1) 4,366 (22.0) 54.9±11.3 5 (14.8) 21 (10.5) 0.2 0.18±0.04
2007 31 (13.3) 1,123 (5.6) 46.1±16.9 3 (8.9) 28 (14.1) 0.2 0.18±0.04
2008 40 (17.1) 2,264 (11.3) 55±8.9 7 (20.5) 33 (16.5) 0.2 0.18±0.03
2009 45 (19.3) 3,965 (19.9) 56.2±10.3 5 (14.7) 40 (20.1) 0.2 0.18±0.04
2010 50 (21.5) 5,396 (27.0) 55±11.3 6 (17.6) 44 (22.1) 0.2 0.18±0.04
Total 233 (100) 19,934 (100) 54.2±11.4 34 (100) 199 (100) 0.2 0.18±0.04
  1. Note: Median, mean and standard deviations or number and percentages as appropriate. LGE, late gadolinium enhancement. Studies that had both LGE and perfusion results were categorized as LGE . For these studies, total gadolinium dose is shown.